Skip to content

TO EVAUATE THE EFFECT OF INDIVIDUALISED HOMOEOPATHIC TREATMENT IN PATIENTS OF ATOPIC DERMATITIS ASSOCIATED WITH GENERALISED ANXIETY

EFFECT OF INDIVIDUALISED HOMOEOPATHIC TREATMENT IN PATIENTS OF ATOPIC DERMATITIS ASSOCIATED WITH GENERALISED ANXIETY - AN OPEN LABEL PROSPECTIVE STUDY - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067535
Enrollment
40
Registered
2024-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Individualised Homoeopathhic Medicine: Detailed and thorough case taking of the patient shall be done in accordance with the direction laid down by Dr. Hahnemann in the Organon of Medic

Sponsors

National Institute of Homoeopathy, Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Atopic dermatitis fulfilling Hanifin and Rajka diagnostic criteria associated with generalised anxiety (having GAD-7 score of more than or equal to 10). Patient age group 18-60 years, of any gender, of any religion, of any socio-economic background. Patents must be knowing either Hindi or English or Bengali. Patients willing to give written informed consent. Patients already undergoing regular oral/topical conventional therapy for atopic dermatitis may be recruited only if the medications are stopped completely 3 months prior to the treatment.

Exclusion criteria

Exclusion criteria: Patient who are already taking medication for Generalised Anxiety for long term or to be decided as per the present general health of the patient. Patient suffering from any life threatening/ Psychiatric/ illness or Immuno-compromised state or other significant disease condition. Patients with malignancy of any organ. Pregnant or lactating women. Substance abuse and/or dependence. Patients not willing to give consent for participation in the study. Patients not willing to undergo any investigations if advised. Patients who continue to be under other method of treatment or therapy.

Design outcomes

Primary

MeasureTime frame
Eczema Area and Severity Index (EASI) score for atopic dermatitis. Generalised Anxiety Disorder (GAD-7) score for generalised anxietyTimepoint: At baseline and 6th month

Secondary

MeasureTime frame
To ascertain and shortlist the most frequently indicated Homoeopathic medicines in the treatment of patients of atopic dermatitis associated with generalised anxiety. To ascertain the predominant miasm in treatment of patients of atopic dermatitis associated with generalised anxiety. Timepoint: 6 months

Countries

India

Contacts

Public ContactDr INDRANI CHAKRABARTI

National Institute of Homoeopathy (Kolkata)

indrani.abc@gmail.com9433902555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026